MedTrace Logo

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

NCT00807794 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2008-12-12

No results posted yet for this study

Summary

To evaluate the clinical safety of different doses of MEDI-507 through day 33.

Conditions

Interventions

DRUG

MEDI-507

0.012 mg/kg dose given twice between 60 to 72 hours apart

DRUG

MEDI-507

0.06 mg/kg dose given twice between 60 to 72 hours apart

DRUG

MEDI-507

0.12 mg/kg dose given twice between 60 to 72 hours apart

DRUG

MEDI-507

0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)

DRUG

MEDI-507

0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)

Sponsors & Collaborators

  • MedImmune LLC

    lead INDUSTRY

Principal Investigators

  • J. Bruce McClain, M.D. · MedImmune LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-02-28
Primary Completion
1997-11-30
Completion
1998-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00807794 on ClinicalTrials.gov